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BAL = bronchoalveolar lavage; ECP = eosinophil cationic protein; FEV1 = forced expiratory volume in 1 s; GM-CSF = granulocyte macrophage-
colony stimulating factor; JAK = Janus kinase; Th = T-helper (cell).
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Introduction
Several allergic diseases, such as nasal rhinitis, nasal
polyps, asthma, idiopathic eosinophilic syndromes, and
atopic dermatitis, have prominent inflammatory compo-
nents that are characterized by pronounced eosinophilic
infiltration [1]. As a result, the role of chronic pulmonary
inflammation in the pathophysiology of asthma has been
studied extensively in human and in animal models. In
asthma, pulmonary inflammation is characterized by
edema, decreased mucociliary clearance, epithelial
damage, increased neuronal responsiveness, and bron-
choalveolar eosinophilia [1].
Eosinophils form in the bone marrow from myeloid precur-
sors in response to cytokine activation, and are released
into the circulation following an appropriate stimulus [2].
Once in the circulation they accumulate rapidly in tissue,
where they synthesize and release lipid mediators that can
cause edema, bronchoconstriction and chemotaxis, and
secrete enzymes and proteins that can damage tissue [2].
The eosinophil is therefore an ideal target for selectively
inhibiting the tissue damage that accompanies allergic dis-
eases, without inducing the immunosuppressive conse-
quences that can arise from systemic use of pleiotropic
drugs such as steroids.
Interleukin-5 acts as a homodimer, and is essential for mat-
uration of eosinophils in the bone marrow and their release
into the blood [3–6]. In humans, interleukin-5 acts only on
eosinophils and basophils, in which it causes maturation,
growth, activation, and survival [7,8]. This specificity occurs
because only those cells possess the interleukin-5 recep-
tor. The functional high-affinity interleukin-5 receptor (250
pmol/l) is composed of two subunits: an a-subunit that is
unique to interleukin-5, and a bc-subunit that is shared with
interleukin-3 and granulocyte macrophage-colony stimulat-
ing factor (GM-CSF) [9,10].
In animals and in humans, inhibiting interleukin-5 with
monoclonal antibodies can reduce blood and broncho-
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alveolar eosinophilia caused by allergic challenge or
chronic disease [11–14]. Therefore, exclusively inhibiting
the actions of interleukin-5 can suppress at least one of
the alleged causes of asthma, namely tissue damage due
to eosinophil accumulation during pulmonary inflammation.
Although a relationship exists between pulmonary
eosinophilia and asthma in humans [15,16], the correlation
in animal models between airway hyperreactivity and
eosinophilia is less convincing [13,17,18]. However, selec-
tive inhibition of interleukin-5 by antibodies can block
hyperreactivity in nonhuman primates [14]. Much of the
same biology is evident in interleukin-5-knockout mice [19].
Although these mice can produce constitutive levels of
eosinophils, they do not react to an allergic challenge with
blood or lung eosinophilia or hyperreactivity, compared to
normal controls. Of interest, interleukin-5-knockout mice do
not develop an enhanced Mesocestoides corti infection
after exposure, as measured by the worm burden [20].
Clinical trials with humanized antibodies against inter-
leukin-5 have begun. In the current trials these therapeu-
tics inhibit eosinophilia in asthmatic persons, but an effect
on lung function has yet to be established [21,22]. Further
trials designed to measure eosinophil accumulation and
lung function in asthmatic persons are currently underway,
and will help to define the role of interleukin-5 and
eosinophils in general in this disease.
Genomics and biochemistry of the
interleukin-5 system
There are clusters of T-helper (Th)2-type cytokine genes,
including that which encodes interleukin-5, on human
chromosome 5q and in the mouse on chromosome 11q,
indicating a common evolutionary origin [23]. The cDNA
that encodes murine interleukin-5 was cloned in 1986
from a T-cell line, followed by isolation of interleukin-5
cDNA from a human T-cell leukemia line [24,25] using a
murine interleukin-5 cDNA as a probe. No overall signifi-
cant amino acid sequence homology was found to exist
with other cyokines, except for short stretches in the
murine interleukin-3, murine GM-CSF, and murine inter-
feron-g proteins [25]. Furthermore, in the interleukin-5 pro-
moter region there are short stretches of conserved
sequence motifs, designated CLE 0, CLE 1 and CLE 2,
which are also found in the 5¢-flanking regions of the inter-
leukin-3, interleukin-4, and GM-CSF genes [23,26].
Biologically active interleukin-5 is a disulfide-linked homod-
imer that is held together by the highly conserved cysteine
residues that orient the monomers in an antiparallel arrange-
ment [27,28]. The higher homology of mouse and human
interleukin-5 found in the carboxyl-terminal compared with
the amino-terminal half is consistent with the binding site for
the interleukin-5 receptor that resides between helices C
and D at an arginine-rich region that comprises residues 89
through 92 [29–31]. The broad range of apparent molecu-
lar weights (45–60 kDa) of recombinant murine interleukin-
5 and human interleukin-5 results from differential
glycosylation, but deglycosylated interleukin-5 retains full
biologic activity [32]. A crystal structure shows that human
interleukin-5 is a novel two-domain configuration with each
domain requiring the participation of two chains, with a high
degree of similarity to the cytokine fold found in GM-CSF,
interleukin-3, and interleukin-4 [33].
Like interleukin-4, interleukin-5 is produced by T cells that
belong to the Th2 but not the Th1 subset. By virtue of the
pattern of cytokines that they synthesize, Th2 cells are
thought to control the growth and effector function of those
cell types that are involved in allergic inflammatory
responses [34–38]. As with other cytokines, regulation of
interleukin-5 production is thought to result from activation
of gene transcription [37]. Interleukin-5 synthesis is also
regulated at the level of mRNA stability [39]. Interleukin-5
gene expression requires de novo protein synthesis, and is
effectively inhibited by glucocorticoids and cyclosporine
[36,37,40]. Furthermore, in vivo depletion of T cells in a
mouse model of pulmonary inflammation reduces pulmonary
eosinophilia, and interleukin-5 and other cytokine mRNA
levels [38]. Mast cells and eosinophils also synthesize inter-
leukin-5, indicating that autocrine production of interleukin-5
may contribute to the chronicity of inflammation [41,42].
The interleukin-5 receptor is in the type I cytokine family,
which includes receptors for interleukin-2 through inter-
leukin-7, GM-CSF, granulocyte-colony stimulating factor,
and erythropoietin [10,43]. These receptors are integral
membrane glycoproteins with amino-termini directed extra-
cellularly, a single membrane-spanning domain, and several
conserved features [10,43]. The human interleukin-5
receptor has a Kd of 170–330 pmol/l, and is expressed on
eosinophils and eosinophilic sublines of the HL60 cell
[44,45]. The high-affinity interleukin-5 receptor is com-
posed of two noncovalently associated subunits: a and b.
The 60 kDa human interleukin-5 receptor a-chain binds
mouse and human interleukin-5 with relatively high affinity
(Kd = 1 nmol/l) [46], but does not induce signal transduc-
tion. Interaction of the a-subunit/interleukin-5 complex with
the b-subunit, which is shared with the GM-CSF receptor
and the interleukin-3 receptor, increases affinity to approxi-
mately 250 pmol/l and facilitates functional activity [9]. A
soluble receptor form of the interleukin-5 receptor a has
been identified, which antagonizes both binding and func-
tion of interleukin-5, and may protect against excessive
eosinophil recruitment and activation [9].
Protein tyrosine kinases that physically associate with
cytokine receptors and become activated after ligand
binding have been identified [47]. Utilizing the b-subunit,
interleukin-3, GM-CSF and interleukin-5 primarily activate
Janus kinase (JAK)2 in response to ligand–receptorc
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
binding [47,48]. Activation of the JAK proteins is normally
associated with autophosphorylation. Like interleukin-3
and GM-CSF, interleukin-5 induces rapid tyrosine phos-
phorylation of several proteins, further indicating that tyro-
sine kinases are involved in the cellular activation
pathways [47,49]. JAK2 then induces tyrosine phosphory-
lation of STAT5, which activates its DNA-binding ability
[47,49] and the ensuing cell activation [48].
Biology of interleukin-5
In the human, interleukin-5 is selective for eosinophils and
basophils, whereas in the mouse it also acts on B lympho-
cytes [3,7,50]. Of course, eosinophils and basophils are
two predominant effector cell types in allergic inflamma-
tion. By associating with its receptor, interleukin-5 effects
eosinophil growth and differentiation [4,5,50,51], migra-
tion [8,50,52], activation and effector function [50,53,54],
and survival [50,55]. As opposed to interleukin-3 or GM-
CSF, only interleukin-5 promotes growth and differentia-
tion to mature eosinophils in the bone marrow.
Interleukin-3 and GM-CSF are also less selective than
interleukin-5, stimulating the production of other granulo-
cytes such as mast cells and neutrophils, respectively
[50,56]. Because eosinophils are a dominant cell type in
allergic reactions, this exquisite specificity makes inter-
leukin-5 an excellent target for attenuating these
responses. In fact, prolonged eosinophil survival and
decreased eosinophil apoptosis caused by interleukin-5
are reversed by glucocorticoids [57,58], which accounts
for at least some of the efficacy or these agents.
Activated eosinophils synthesize and release mediators,
and secrete preformed granule constituents [59–62]. The
eosinophil responds to a unique set of physiologic trig-
gers, including secretory immunoglobulin A [59], which
result largely from a Th2-type lymphocyte response.
Eosinophils and neutrophils respond to many common
stimulators, such as C5a, phorbol myristate acetate,
zymosan, and formyl-methionyl-leucyl-phenylalanine [25,
60–65], with a respiratory burst, activation of phospholi-
pases, production of eicosanoids, and secretion of pre-
formed granule contents such as peroxidases and
proteinases, including lysozyme and collagenases
[63–65]. On the other hand, the ability to store and
secrete the cationic low-molecular-weight proteins major
basic protein, eosinophil cationic protein (ECP), and
eosinophil-derived neurotoxin (EDN) is unique to the
eosinophil [66]. Major basic protein and ECP can lyse
cells and can cause tissue damage at low concentrations
[67–69]. Although EDN also has a pI of 11, it is not as
innately toxic to tissue, indicating that there is more to this
cytotoxicity than just the positive charge [67].
Animal models of interleukin-5 action
As a result of its efficacy and selectivity, interleukin-5 is an
ideal drug development target for allergic eosinophil-
mediated diseases. With the development of neutralizing
monoclonal antibodies to interleukin-5, interleukin-5-
deficient mice, in situ hybridization methodology, and
immunocytochemical techniques, it has been possible to
investigate the role of interleukin-5 in allergic inflammatory
responses in animals and humans.
Because the activity of interleukin-5 is restricted to
eosinophils, it should be an ideal target to block this
response in the lungs of allergic animal models of asthma,
and has been studied in several species. Sensitized
guinea pigs respond to allergic challenge with bronchial
hyperresponsiveness and infiltration of eosinophils into
lung tissue and bronchoalveolar lavage (BAL) fluid
[11,13,70]. Monoclonal antibodies to interleukin-5 inhibit
these pulmonary responses [13]. In contrast, larger doses
of an anti-interleukin-5 antibody are needed to block the
hyperreactivity than are needed to block the eosinophilia.
This suggests either that interleukin-5 has effects on bron-
choconstrictor reactivity that are independent of its effects
on eosinophils, or that eosinophil activation, degranulation
and release of its cytotoxic products, which were not mea-
sured in these studies, are the relevant aspects of
eosinophil function that correlate with the development of
the hyperreactivity. Indeed, it has been shown [71] that
delivery of recombinant human interleukin-5 to the lungs of
naïve guinea pigs increases eosinophils and neutrophils in
the lungs and bronchoalveolar fluid, but this condition is
not associated with augmented bronchoconstrictor
responsiveness. However, recent studies have shown that
administration of recombinant interleukin-5 to isolated
airway smooth muscle from both rabbits and humans
results in increased reactivity to acetylcholine [72]. In
these studies the interleukin-5-induced hyperreactivity was
abated by blocking the activity of interleukin-1, and
interleukin-1b mRNA and protein levels are increased by
interleukin-5. Interleukin-5 may contribute to airway hyper-
reactivity by both indirect and direct mechanisms. In fact, it
may work indirectly by releasing granule proteins from
eosinophils that act as endogenous allosteric antagonists
at inhibitory presynaptic muscarinic M2 receptors, aug-
menting bronchoconstrictor responses to vagal nerve stim-
ulation [73]. It may also work directly by mediating
synthesis of interleukin-1b in airway smooth muscle [72].
As with guinea pigs, antigen challenge to the lungs of sen-
sitized mice causes an influx of eosinophils into the BAL
fluid and lung tissue [74]. This effect is inhibited when
monoclonal antibodies to interleukin-5 are given before
the antigen challenge [75]. There is also increased expres-
sion of mRNA for Th2 cytokines such as interleukin-5 and
interleukin-4 in the lungs of allergic mice [38]. To a lesser
extent than are T lymphocytes, mast cells are involved in
the development of pulmonary eosinophilia in allergic mice
after single provocation by antigen [76], but are much less
important in the pulmonary eosinophilia that occurs after a
Available online http://respiratory-research.com/content/2/2/071multiple antigen challenge paradigm [77]. Mice have been
developed using standard technology that are deficient in
interleukin-5 [20]. These mice produce constitutive levels
of eosinophils driven by other cytokines, and have normal
circulating levels of immunoglobulin E, but do not mount
an eosinophilic response to allergic challenge.
After multiple exposure to inhaled antigen, sensitized mice
exhibit airway hyperreactivity [19,20]. When challenged in
this manner, both the lung and lavage eosinophilia and the
airway hyperreactivity to cholinergic agents are blocked by
anti-interleukin-5 antibodies [20]. In addition, in sensitized
interleukin-5-deficient mice receiving multiple challenges,
the hyperreactivity is eliminated along with the airway
eosinophilia [19,20]. In a variety of knockout and trans-
genic mice that were further modified by the administra-
tion of cytokines, chemokines or antibodies, there appear
to be significant interactions among these proteins with
regard to establishing eosinophilia and airways hyperreac-
tivity [78]. Whereas interleukin-4 and interleukin-13 are
redundant with regard to these inflammatory parameters,
interleukin-5 plays a distinct role in both. Furthermore,
interleukin-5 and eotaxin synergistically enhance
eosinophilia and airway hyperreactivity in allergic mice by
a CD4+ T-cell-dependent mechanism [79]. To some
degree, these observations are dependent on the back-
ground strain of mouse [20,78].
Interleukin-5 has also been identified as an important
cytokine in regulating human eosinophil survival in asth-
matic persons after antigen challenge [57]. Inhibition of
interleukin-5 activity during an established pulmonary
eosinophilia could, therefore, cause tissue damage due to
destruction of eosinophils and release of their inflamma-
tory mediators. However, in allergic mice, administration of
an antibody to interleukin-5 after antigen challenge, when
lung eosinophilia was already established, did not
increase tissue damage in the lungs [75]. These results
have important therapeutic implications for the potential
use of interleukin-5 inhibitors in the treatment of inflamma-
tory airway disorders.
Allergic cynomolgus monkeys are also subject to an
inflammatory cell influx into the airways, an early and late-
phase bronchoconstriction, and bronchial hyperrespon-
siveness [14,80]. Treatment with a monoclonal antibody
to interleukin-5 inhibits these responses to antigen provo-
cation [14]. TRFK5, a monoclonal anti-interleukin-5 anti-
body, at an intravenous dose of 0.3 mg/kg inhibits lavage
eosinophilia to 70%, while completely blocking the hyper-
reactivity to histamine. Furthermore, inhibition of both the
pulmonary eosinophilia and bronchial hyperresponsive-
ness lasted for at least 3 months after a single treatment
because of the long circulating lifetime of the antibody.
Hence, in several animal models of asthma, blockade of
interleukin-5 activity suppressed both eosinophilia and
changes in lung function, but the causal relationship
between these two effects is somewhat tenuous.
Although there is often a correlation between lung
eosinophilia, ECP in BAL fluid, and a decreased forced
expiratory volume in 1 s (FEV1) in humans [81], this does
not necessarily indicate that the eosinophils are responsi-
ble for the decreased lung function. In fact, in several
animal models there is a lack of correlation between
reduced levels of lung eosinophils and improved lung
function, suggesting that a critical activation step is
missing [13–18]. In reality, there are no animal models
that precisely duplicate the chronic nature of asthma.
Interleukin-5 in human asthma
Atopic asthmatic persons have increased expression of
Th2-type cytokine (interleukin-2, interleukin-3, inter-
leukin-4, interleukin-5, and GM-CSF) mRNA in both BAL
fluid and in bronchial biopsies as compared with healthy
volunteers, but there is no difference between the two
groups in the expression of Th1-type cytokine mRNA such
as interferon-g [82–85]. The predominant source of inter-
leukin-4 and interleukin-5 mRNA in asthmatic persons is
the T lymphocyte, and the CD4+ and CD8+ T-cell popula-
tions express elevated levels of activation markers includ-
ing interleukin-2 receptor (CD25), human leukocyte
antigen-DR, and the very late activation antigen-1
[84,86–90]. These results suggest that atopic asthma is
associated with activation of the interleukin-3, interleukin-
4, interleukin-5, and GM-CSF gene cluster, a pattern that
is consistent with a Th2-like T-lymphocyte response [85].
Interleukin-5 mRNA is also found in activated eosinophils
and mast cells in tissues from patients with atopic dermati-
tis [91–93], allergic rhinitis [94,95], and asthma [82,89],
raising the possibility that interleukin-5 arises from multiple
sources in atopic individuals.
Eosinophil infiltration into the airways after allergen chal-
lenge is a consistent feature of atopic asthmatic persons
[96–98]. Interleukin-5 is predominantly an eosinophil-
active cytokine in the late-phase response to antigen
challenge [99,100], and is important for the recruitment
and survival of eosinophils [57,99]. On the other hand,
interleukin-5 is probably not important in the acute
response to allergen challenge in asthmatic persons.
Indeed, interleukin-5 is not detectable in the BAL fluid of
mildly asthmatic persons shortly after allergen provoca-
tion [100]. Interleukin-5 may also be important for the
recruitment of eosinophils from blood vessels into
tissues, because topical administration of recombinant
human interleukin-5 to the nasal airway of persons with
allergic rhinitis induced eosinophil accumulation into the
nasal mucosa [101,102]. Interleukin-5 may also induce
activation of eosinophils that are resident to inflamed
tissue, but this effect may be secondary to activation of
secretory immunoglobulin A [103].
Respiratory Research    Vol 2 No 2 Greenfeder et alSeveral studies have demonstrated a correlation between
the activation of T lymphocytes, increased concentration of
interleukin-5 in serum and BAL fluid, and increased severity
of the asthmatic response [87,104–106]. In a study of 30
asthmatic persons, Robinson et al [86] found a strong cor-
relation between the number of BAL cells that expressed
mRNA for interleukin-5, the magnitude of baseline airflow
obstruction (FEV1), and bronchoconstrictor reactivity to
methacholine. Furthermore, Zangrilli et al [106] found
increased levels of interleukin-4 and interleukin-5 in the
BAL fluid of asthmatic persons who had a late-phase
response to antigen, but not in asthmatic persons who only
demonstrated an early-phase response to antigen chal-
lenge. Motojima et al [104] compared serum levels of inter-
leukin-5 in asthmatic patients during an exacerbation and in
remission of asthma. Higher levels of serum interleukin-5
were found in each person during exacerbation, and
patients with severe asthma had higher levels of serum
interleukin-5 than did control individuals or patients with
mild asthma. It is interesting to note that interleukin-5 levels
were reduced in the serum of patients with moderate-to-
severe asthma who were receiving oral glucocorticoids for
control of their asthma [104,106]. These results are
consistent with in vitro studies that show a potent inhibitory
effect of corticosteroids on gene expression and on the
release of pro-inflammatory cytokines, including interleukin-5,
from inflammatory cells [107].
The link between interleukin-5, eosinophils, and asthma is
currently under investigation using two humanized mono-
clonal antibodies specific for interleukin-5 that have been
advanced into the clinic for evaluation as therapies for
asthma. SCH55700 (reslizumab) is a humanized mono-
clonal antibody with activity against interleukin-5 from
various species [108]. SB240563 (mepolizumab) is also a
humanized antibody with specificity for human and primate
interleukin-5 [109,110].
SCH55700 has an affinity for human interleukin-5 of
81 pmol/l and a 50% inhibitory concentration for inhibition
of human interleukin-5-mediated TF-1 cell proliferation of
45 pmol/l. The efficacy of SCH55700 was further evalu-
ated preclinically in a number of animal models. In a dose-
dependent manner, SCH55700 inhibited total cell and
eosinophil influx into BAL fluid, bronchi, and bronchioles of
allergic mice for up to 8 weeks after a single 10 mg/kg
dose and for 4 weeks after a single 2 mg/kg dose. Addi-
tional studies in allergic mice indicated that the combina-
tion of SCH55700 with an oral steroid (prednisolone)
significantly increased the efficacy over that of either
agent administered alone [108]. In allergic guinea pigs,
SCH55700 caused a dose-dependent decrease in pul-
monary eosinophilia and inhibited the development of
allergen-induced airway hyperresponsiveness to sub-
stance P. It also inhibited the accumulation of total cells,
eosinophils, and neutrophils in the lungs of guinea pigs
exposed to human interleukin-5. SCH55700 had no effect
on the numbers of inflammatory cells in unchallenged
animals or in animals challenged with GM-CSF, and had
no effect on the levels of circulating total leukocytes [108].
In cynomolgus monkeys naturally allergic to Ascaris suum,
postchallenge pulmonary eosinophilia was significantly
decreased for up to 6 months after a single 0.3 mg/kg
intravenous dose of SCH55700 [108].
A rising single-dose phase I clinical trial was conducted
with SCH55700 in patients with severe persistent asthma
who remained symptomatic despite intervention with high-
dose inhaled or oral steroids [22]. The two highest doses
of SCH55700 significantly decreased peripheral blood
eosinophils, with inhibition lasting up to 90 days after the
1 mg/kg dose. There was also a trend toward improve-
ment in lung function at the higher doses 30 days after
dosing, with mean FEV1 increasing by 11.2 and 8.6% in
the 0.3 and 1.0 mg/kg groups, respectively, versus 4.0%
in the placebo group [22].
Preclinical studies with SB240563 in cynomolgus monkeys
indicated that peripheral blood eosinophils were decreased
as a result of administration of the antibody [109,110]. Inter-
estingly, maximal inhibition of peripheral blood eosinophils
(80–90% of baseline) occurred 3–4 weeks after dosing
(1 mg/kg subcutaneously), whereas maximal blood levels of
the antibody were obtained 2–4 days after dosing, with a
half-life of approximately 14 days.
SB240563 has also recently been tested in asthmatic
persons in a clinical single-dose safety and activity study
[21]. Patients with mild asthma were administered a single
intravenous dose of SB240563 at either 2.5 or 10 mg/kg,
or placebo. Patients were challenged with allergen
2 weeks before and 1 and 4 weeks after dosing. Periph-
eral blood and sputum eosinophil levels were measured,
and early-phase and late-phase asthmatic responses were
assessed by measuring the percentage fall in FEV1
induced by allergen challenge. Both doses of SB240563
caused a significant reduction in peripheral blood
eosinophils. Eosinophil counts were reduced in the
10 mg/kg dose group by approximately 75% for up to
16 weeks, and in the 2.5 mg/kg dose group by approxi-
mately 65% for up to 8 weeks. Postchallenge sputum
eosinophils were also reduced in the 10 mg/kg dose
group. Neither dose of SB240563 attenuated the fall in
FEV1 induced by allergen challenge in these mildly
asthmatic persons.
With both of these antibodies showing acceptable safety
profiles, larger studies can be conducted to determine the
impact of blocking interleukin-5 on the pathophysiology of
asthma and other eosinophil-related diseases. Only when
these clinical trials are conducted will we be able to deter-
mine whether interleukin-5-based therapy in humans will
Available online http://respiratory-research.com/content/2/2/071
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models.
Conclusion
There are circumstantial but compelling data that implicate
interleukin-5 in diseases that involve eosinophils. Inter-
leukin-5 is produced in lymphocytes, mast cells,
eosinophils, and airway smooth muscle and epithelial
cells, and is primarily responsible for the maturation and
release of eosinophils in the bone marrow. In humans, it is
a very selective cytokine because only eosinophils and
basophils possess a type-1 cytokine receptor for inter-
leukin-5 with a specific a-subunit and the bc-subunit that
confers high-affinity binding and signal transduction. A
specific inhibitor of interleukin-5 could, therefore, attenu-
ate pulmonary inflammation and the consequent patho-
physiology without the potential for immunosuppressive
side effects that exist with steroids.
Interleukin-5 in the circulation has been reduced by potent,
neutralizing anti-interleukin-5 monoclonal antibodies. As a
result, eosinophils have been attenuated for long durations
in various animal models of eosinophil accumulation. In
some but not all of these animal models, inhibition of tissue
or BAL eosinophilia correlates with decreased pathophysi-
ology. In addition, interleukin-5-knockout mice do not
respond to an allergic challenge with blood or tissue
eosinophilia. Furthermore, these mice are not overly sensi-
tive to parasitic infection and, as opposed to their normal
counterparts, are not hyperreactive to cholinergic chal-
lenge to the lungs. By contrast, although eosinophil levels
were reduced by an anti-interleukin-5 antibody in a human
allergic challenge model, there was no reduction in hyper-
reactivity. In a phase I clinical trial with another humanized
anti-interleukin-5 antibody, eosinophils were reduced for
90 days in severe steroid-dependent asthmatic persons.
Nevertheless, ongoing phase II studies are required to
determine the utility of this approach in treating asthma and
other eosinophilic diseases.
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